Lexaria expands GLP-1-H24-4 trial with 5th tirzepatide arm

Lexaria Bioscience Corp.

Added 5th study arm investigating DehydraTECH-tirzepatide capsules in GLP1-H24-4 diabetes trial.
Existing four arms increased from 20 to 24 subjects; new arm will recruit 24 subjects.
Change Order with Novotech adds ~AU$1,900,000 to approved budget.
Human research ethics committee approval for the new arm was granted Feb 24, 2025.
Study evaluates DehydraTECH delivery of cannabidiol and GLP-1 agonists in pre/Type II diabetes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.